
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc. demonstrated a notable improvement in gross margins year-over-year, attributed primarily to a higher mix of consumables revenue. The company reported significant utilization of its Revio platform, which reached its highest level since launch, indicating strong demand and successful market penetration. Furthermore, management expressed optimism regarding sequential growth in Vega placements, suggesting potential for continued revenue expansion throughout the year.
Bears say
The outlook for Pacific Biosciences of California Inc is negative primarily due to an anticipated decline in gross margins, projected to be lower in Q2 compared to the 40.4% margin reported in Q1, indicating potential profitability concerns. Additionally, if the company experiences stagnant utilization rates or if demand for new instruments fails to meet expectations, its financial targets for 2026 could be jeopardized, potentially leading to adverse reactions in the stock price. Furthermore, the ongoing demand weakness in the life sciences tools sector, particularly in China, is expected to continue throughout 2023 and into 2024, contributing further to the negative financial outlook.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares